---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-25-013703"
form_type: "8-K"
ticker: "BGMS"
cik: "0001130166"
company_name: "Bio Green Med Solution, Inc."
filed_at: "2025-09-16T23:59:59+00:00"
generated_at: "2026-05-17T06:26:45.525730+00:00"
event_type: "regulatory"
sentiment: "negative"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Bio Green Med receives Nasdaq deficiency notice for preferred stock (BGMSP) over minimum MVPHS

## Summary
- Nasdaq notified that BGMSP's Market Value of Publicly Held Shares fell below $1M for 30 consecutive business days.
- Company has 180 days until March 10, 2026 to regain compliance by achieving MVPHS of at least $1M for 10 consecutive days.
- Deficiency does not affect common stock (BGMS) listing; preferred stock continues to trade during cure period.
- Company will evaluate options if compliance not regained, including potential delisting and Nasdaq appeal process.

## SEC filing metadata
- accession: 0001493152-25-013703
- form_type: 8-K
- ticker: BGMS
- cik: 0001130166
- company_name: Bio Green Med Solution, Inc.
- filed_at: 2025-09-16T23:59:59+00:00
- event_type: regulatory
- sentiment: negative
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 3.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1130166/000149315225013703/0001493152-25-013703-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1130166/000149315225013703/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-25-013703
- JSON: https://secwatch.observer/filing/0001493152-25-013703.json
- Plain text: https://secwatch.observer/filing/0001493152-25-013703.txt

## Source-grounded claims
- claim_id: ee30ebed11cef6b35f2a143b541a1ba6f06dc4ce
  claim: Bio Green Med Solution, Inc. received a nasdaq deficiency notice notice regarding market value (rules 5460(a)(2), 5810(c)(3)(D)).
  evidence_excerpt: September 11, 2025, Bio Green Med Solution, Inc. ( fka Cyclacel Pharmaceuticals, Inc.) received a letter from the listing qualifications department staff (the “Staff”) of The Nasdaq Stock Market (“Nasdaq”), notifying the Company that its 6% Convertible Exchangeable Preferred Stock (listed on the Nasdaq Capital Market under the symbol “BGMSP”) (the “Preferred Stock”) no longer complies with the requirement under Nasdaq Listing Rule 5460(a)(2) to maintain a minimum Market Value of Publicly Held Shares (as such terms are defined under the Nasdaq Listing Rules, “MVPHS”) of $1 million. The Staff’s
  evidence_url: https://www.sec.gov/Archives/edgar/data/1130166/000149315225013703/0001493152-25-013703-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.